MedTrace Logo

Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment

NCT02460133 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2024-08-23

No results posted yet for this study

Summary

This pilot study is crucial to determining whether treating individuals who are at high risk for transmission or re-infection will impact HCV reinfection rates. It will establish the feasibility of DAA treatment in corrections facilities, as well as delineate the underlying immune basis of HCV cure and reinfection.

Conditions

  • Hepatitis C Virus

Interventions

DRUG

Paritaprevir

DRUG

Ritonavir

DRUG

Dasabuvir

DRUG

Ombitasvir

DRUG

Ribavirin

In genotype 1b individuals without cirrhosis, treatment will NOT include ribavirin.

Sponsors & Collaborators

  • Provincial Correction Centre (PEI)

    collaborator UNKNOWN

  • Nova Scotia Health Authority

    lead OTHER

Principal Investigators

  • Lisa Barrett, MD PhD FRCPC · Department of Medicine, Division of Infectious Diseases, Nova Scotia Health Authority, Dalhousie University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-10
Primary Completion
2025-10-31
Completion
2025-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02460133 on ClinicalTrials.gov